Kimmtrak
| Chemical Name | tebentafusp-tebn |
| Dosage Form | Injection (subcutaneous; 100 mcg/0.5 mL) |
| Drug Class | Peptides |
| System | Ocular |
| Company | Immunocore |
| Approval Year | 2022 |
Indication
- For the treatment of HLA-A*02:01-positive adult patients with unresectable or metastatic uveal melanoma